FMCQFNYSEServices-Misc Health & Allied Services, NECUS GAAP · USD

Fresenius Medical Care AG

Fresenius Medical Care AG is a renal care company built around dialysis treatment and related products for people with chronic kidney disease and end-stage renal disease. Its business combines a global network of dialysis clinics with the manufacture and supply of dialysis machines, dialyzers, and related renal care products, and it operates through both healthcare delivery and product segments.

Revenue19.6bn USD
+1.5 %y/y
Operating profit (EBIT)1,897m USD
+29.6 %y/y
EBIT margin9.7%
+2.1 ppy/y
Net income978m USD
+81.9 %y/y
Free cash flow1,766m USD
+4.7 %y/y

Fiscal year 2025 · change from previous year

Development 2022–2025

05101520bn USD2022: 19.4 bn USD2022: EBIT 1.6 bn USD20222023: 19.5 bn USD2023: EBIT 1.5 bn USD20232024: 19.3 bn USD2024: EBIT 1.5 bn USD20242025: 19.6 bn USD2025: EBIT 1.9 bn USD202519.61.9
RevenueOperating profit (EBIT)

Business

Share of revenue
Care Delivery55 %

In-clinic dialysis services and extracorporeal therapies for kidney disease patients.

Care Enablement35 %

Manufacture and distribution of dialysis products, equipment, and related services.

Value-Based Care10 %

Kidney care contracting, clinical management, and tech-enabled care coordination.

Customers

The company serves patients with chronic kidney disease and end-stage renal disease through dialysis clinics and related care services. It also sells dialysis equipment and consumables to healthcare providers, clinics, and care systems that deliver renal therapy. In addition, its value-based kidney care activities address payors and provider networks that manage total cost and outcomes for kidney populations.

Dialysis patients

Patients with CKD or ESRD receiving recurring dialysis treatments in FMC clinics.

Healthcare providers

Hospitals, clinics, and renal care providers buying dialysis machines and consumables.

Payors and managed care organizations

Private insurers and government programs contracting for kidney care management and shared-savings arrangements.

Nephrology networks

Physician groups and care networks using platforms and services for coordinated kidney care.

Strategy

The company is focused on integrating dialysis care delivery with dialysis products and value-based kidney care models. Its strategic direction centers on using its clinical network, proprietary informatics, and patient engagement tools to improve kidney outcomes while supporting recurring demand for therapies and consumables. Capital allocation discipline and shareholder returns are presented as part of its broader execution framework.

Strengthen integrated renal care modelMedium term

Combining clinics, products, and care management increases patient retention and supports recurring demand.

Scale value-based kidney careMedium term

Shared-savings and risk-based contracts can deepen payor relationships and broaden addressable care models.

Improve capital efficiencyShort term

Capital discipline supports shareholder returns while preserving flexibility for operational investment.

Geography

Fresenius Medical Care operates globally, with a large clinic footprint and product sales across North America, Europe, and other international markets. Its operating model depends on local reimbursement systems, healthcare regulations, and clinical networks, so geography directly affects patient mix, pricing, and service delivery. The reported business description emphasizes worldwide operations rather than a single domestic market.

Risks

The business depends on stable reimbursement, clinical utilization, and patient access to dialysis, so changes in payor policy or care patterns can affect volumes and economics. It also faces operational exposure from healthcare regulation, supply chain execution, foreign exchange, and the complexity of managing clinics and product manufacturing across many jurisdictions. In value-based care, shared-savings or full-risk arrangements create additional variability because outcomes, utilization, and medical costs affect results directly.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Reimbursement and payor policy changes1Healthcare operating complexity2Foreign exchange volatility3Value-based care downside risk4
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Reimbursement and payor policy changesImpact: HighLikelihood: High

    Dialysis and kidney care economics depend heavily on public and private reimbursement rates and coverage rules.

    Exposure: Clinic revenue and care services

  2. Healthcare operating complexityImpact: HighLikelihood: High

    Running thousands of clinics requires staffing, regulatory compliance, and consistent treatment quality.

    Exposure: Care Delivery network

  3. Foreign exchange volatilityImpact: MediumLikelihood: High

    Global operations create translation and transaction exposure across currencies.

    Exposure: International revenues and costs

  4. Value-based care downside riskImpact: MediumLikelihood: Medium

    Shared-loss or full-risk arrangements can reduce earnings if patient costs exceed expectations.

    Exposure: Value-Based Care segment

Accounting

Judgemental items
IFRS 15 and IFRS 17 in value-based care

Different contract types are accounted for differently, affecting revenue presentation and volatility.

Impact: Shared-savings revenue and premium/claim accounting

Lease accounting

A large clinic network creates substantial lease commitments and right-of-use assets.

Impact: Depreciation, interest expense, and operating leverage

Foreign exchange effects

International operations create translation and transactional gains or losses.

Impact: Other operating income and period-to-period comparability

Related-party transactions

The company purchases and sells products with Fresenius SE entities and an equity-method investee.

Impact: Revenue, cost of sales, and disclosure complexity

Publicly listed companies with a comparable business focus.

Last updated: 28/09/2026

Fresenius Medical Care AG (NYSE) – Services-Misc Health & Allied Services, | Financial Analysis – Clarifo